{
    "medicine_id": "e17ee4644a73a76956c8910a2a983197a473f524",
    "platform_id": "DB04987",
    "metadata": {
        "name": "Potiga 50 mg 1 Tablet film coated",
        "composition": "50 mg 1 P113D",
        "clinical_particulars": {
            "therapeutic_indications": "For the potential treatment of cystic fibrosis and bacterial infections",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "P113D has demonstrated activity against CF patient clinical isolates of bacteria that are resistant to traditional antibiotics The compound is stable and maintains activity in sputum of CF patients P113 was determined to be the smallest histatin fragment which retained antimicrobial activity equivalent to that of the parent compound Interestingly synthesizing P113 with D amino acids gave rise P113D a compound that was impervious to enzymatic degradation and maintained the antimicrobial activity of the parent compound P113D also has very potent in vitro activity against a variety of Gram negative and positive bacteria including i P aeruginosa i i S aureus i i H influenzae i i S typhimurium i i E coli i i S epidermidis i i S mutans i and i S sobrinus i In the case of i P aeruginosa i and i S aureus i antibacterial activity has been demonstrated against a variety of CF patient clinical isolates which are resistant to traditional antibiotics i P aeruginosa i isolates that produce thick alginate secretions mucoid phenotype are also susceptible to killing by P113D",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}